Radiotherapy is a feasible treatment option in oligometastatic tumors including ovarian cancer. Evidence regarding a potential dose–response relationship remains limited. This study aimed to evaluate the association between radiation dose and treatment outcomes in metastatic ovarian cancer. We retrospectively analyzed all patients with persistent or recurrent metastatic ovarian cancer treated with radiotherapy at our institution between August 2001 and July 2025. Lesion response was assessed according to RECIST version 1.1. The primary endpoint was the 6-month local control rate (LCR). Outcomes were analyzed according to clinicopathological parameters and dose stratification (cutoff: ≥ 39 Gy total dose or ≥ 5 Gy per fraction). In total, 71 patients comprising 107 irradiated lesions with a median clinical follow-up of 7.0 months (IQR 1.0–18.0) were included. Of these, 47 patients received high-dose radiotherapy and 24 received low-dose treatment. Higher radiation doses were associated with improved local control of treated lesions (6-month LCR of 96.1% vs. 86.8%; log-rank p = 0.003). Symptomatic response was assessable in 25 patients (35.2%), with improvement in 17 (68.0%), stability in 3 (12.0%) and deterioration in 5 (20.0%). Among all 32 subsequently treated patients (45.1%), the median time to next systemic therapy was 2.0 months (IQR 0.0–5.0). After radiotherapy, disease remained controlled in five patients (7.0%) each treated for a single lesion. Higher radiation doses were associated with improved local control and may prolong the systemic treatment-free interval. Radiotherapy should be studied as part of multimodal treatment strategies in selected patients with metastatic ovarian cancer.
Cholangiocarcinoma (CCA) represents a diverse group of malignancies. It is often identified at a late stage after the opportunity for curable resection has passed. An international educational meeting on CCA was held in Barcelona in September 2024. The meeting described the challenges with obtaining accurate epidemiological estimates for CCA because of misdiagnosis and marked regional differences, reflecting the prevalence of socioeconomic risk factors. Early-stage CCA is usually asymptomatic, and when symptoms appear, they are nonspecific. Diagnosis and treatment planning should involve a multidisciplinary team (MDT) from the outset. The European Society for Medical Oncology (ESMO) guidelines recommend molecular testing using next-generation sequencing when advanced disease is diagnosed. Biopsy sampling is technically challenging; if insufficient quality tissue is collected for molecular testing, liquid biopsy can be used. If the tumour is unresectable, the recommended first-line treatment is cisplatin + gemcitabine + durvalumab a programmed cell death ligand 1 [PD-L1] inhibitor or pembrolizumab a programmed cell death protein 1 [PD-1] inhibitor. The development of targeted therapies has led to these treatments being recommended as second- or third-line therapy for patients with actionable gene alterations, while 5-fluorouracil-based chemotherapy is recommended for those without. Robust data support the use of ivosidenib in patients with IDH1 mutations (phase 3), and phase 2 trials showed efficacy of pemigatinib and futibatinib for patients with FGFR2 gene fusions, trastuzumab deruxtecan and zanidatamab for patients with HER2 overexpression/amplification, and dabrafenib + trametinib for patients with BRAFV600E mutations. It is hoped that wider dissemination of the content from this meeting will improve outcomes of patients with CCA by encouraging earlier referral, increasing the use of early molecular testing, an MDT approach, and maximising the use of targeted therapies. Continued efforts to raise awareness, implement education outreach opportunities, and involve patient advocacy groups are encouraged to improve CCA outcomes. Cholangiocarcinoma (CCA) is the second most common type of liver cancer. While CCA can be cured if it is diagnosed early enough, it is often identified too late for surgical removal to be feasible. Therefore, there are unmet needs in the management of CCA. An educational initiative called the Expert eXchange meeting in acute myeloid leukaemia and CCA on Targeted therapy (EXACT) program was set up to address the unmet needs in this patient group. The aim of the expert meeting was to discuss how to improve the diagnosis and management of CCA. Expert doctors who treat patients with CCA (oncologists) from 16 countries met in Barcelona, Spain on September 12, 2024, to discuss evidence related to CCA, including using examples of real patients with difficult-to-manage disease. The experts also reviewed recent advances and ongoing research of new therapies, such as molecular biomarkers and targeted therapies, which could improve patient outcomes after CCA is treated. It emerged that there are many interventions that have the potential to positively influence CCA outcomes, including (1) referral to a specialist at the earliest stage of symptom development when CCA is suspected; (2) obtaining a tissue sample for biopsy and molecular testing; (3) testing for genetic mutations, and if present, using therapies targeted to these mutations; (4) raising awareness of CCA through education and outreach initiatives; and (5) involvement of a multidisciplinary team to care for patients throughout their cancer journey.
e13652 Background: Accurate assessment of Ki67 is critical for evaluating cellular proliferation and tumor aggressiveness in breast cancer diagnosis and prognosis. Traditionally, Ki67 immunohistochemistry (IHC) requires appropriate pre-analytical handling, standardized visual scoring, and experienced pathologists for correct interpretation. IHC is a laboratory-intensive procedure that can be affected by inter-observer variability (IOV) and residual heterogeneity. Methods: In this study, we introduce a novel artificial intelligence (AI) model that predicts Ki67 directly from Hematoxylin and Eosin (H&E)-stained Whole Slide Images (WSIs) in patients with hormone receptor-positive early-stage breast cancer. Our model utilizes deep-learning techniques to identify histopathological features that correlate with Ki67 in the whole tissue sample. This makes it hotspot-independent and enables accurate Ki67 predictions for heterogeneous tumor regions and a more comprehensive assessment. The AI-model was developed and validated using over 5200 patients from WSG ADAPT HR+/HER2- and PlanB trials with a 60/40 split and externally validated in ABCSG 6 (N = 1115). The primary objective of the Ki67 model is to correctly classify whether a tumor has low Ki67 (< 20%) or high Ki67 (≥20%) based on pathologist-annotated ground truth, defined as baseline Ki67 assessment by IHC. The area-under-the-curve (AUC) and associated 95%-confidence intervals (CI) were used to evaluate discrimination. To illustrate clinical utility, an exploratory decision threshold was estimated by maximizing the Youden Index in each validation dataset, providing estimates of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Results: The AI-powered Ki67 classifier model demonstrated an AUC of 0.811 (95% CI: 0.791-0.827) in the test split and 0.842 (95% CI: 0.818-0.868) in external validation. Using the exploratory optimal threshold of 0.418 in the test split, the sensitivity and specificity for determining high versus low Ki-67 expression were 77% and 70% respectively. Using the exploratory optimal threshold of 0.616 in the external validation dataset, sensitivity was 73% and specificity was 81%. In the test split and external validation dataset, the PPV was 72% and 64% respectively, and NPV was 75% and 87% respectively. Conclusions: This novel approach to classifying Ki67 directly from H&E-stained slides offers a promising automated solution to streamline diagnostic workflows and enables more accurate, reproducible Ki67 assessment. Ongoing efforts are focused on refining and validating this model to enhance its clinical utility and applicability.